🚀 New IPO Alert! Influx Healthtech Ltd. has received In-Principle Approval from NSE Emerge for its upcoming SME IPO — marking a significant step forward in its journey to becoming one of India’s most prominent CDMOs in the wellness and healthcare manufacturing space. 💡 Market Opportunity: India’s nutraceutical sector is on a powerful growth trajectory — currently valued at USD 30.37 billion in 2024 and expected to soar to USD 64.83 billion by 2030. Influx Healthtech is strategically positioned to capture and create value across this rapidly evolving landscape. 🧪 About Influx Healthtech: Influx is a trusted full-spectrum contract development and manufacturing organization (CDMO), serving global and domestic brands across: Nutraceuticals Cosmetics & Personal Care Ayurvedic & Herbal Products Veterinary Feed Supplements Homecare & Hygiene The company offers high-volume, cost-effective production capabilities for an extensive range of dosage forms — including Softgels, Tablets, Capsules, Gummies, Protein